Subtopic Deep Dive

Herbal Drug Interactions
Research Guide

What is Herbal Drug Interactions?

Herbal Drug Interactions studies pharmacokinetic and pharmacodynamic effects between herbal remedies and conventional pharmaceuticals, particularly cytochrome P450 enzyme modulation.

Research documents adverse reactions from herbal-conventional drug combinations, with global herbal use exceeding 80% for primary healthcare (Ekor, 2014, 3611 citations). Key papers examine interactions in cancer patients, reporting 13-63% herbal prevalence and risks to narrow therapeutic drugs (Sparreboom et al., 2004, 473 citations). Safety monitoring challenges persist amid rising polypharmacy.

15
Curated Papers
3
Key Challenges

Why It Matters

Herbal drug interactions compromise treatment efficacy in comorbid patients, as 13-63% of cancer patients using herbals risk altered chemotherapy pharmacokinetics (Sparreboom et al., 2004). Ekor (2014) highlights adverse reactions from poor safety monitoring, affecting 80% of global primary healthcare users. Calixto (2000) stresses regulatory gaps in phytotherapeutic standardization, guiding clinical risk models for polypharmacy. Greenlee et al. (2017) integrate evidence for safe herbal use in breast cancer supportive care, reducing side effects.

Key Research Challenges

Safety Monitoring Gaps

Adverse reactions from herbals evade detection due to underreporting and lack of pharmacovigilance (Ekor, 2014). Monitoring challenges intensify with 80% global reliance on unregulated products. Standardized systems remain absent.

Cytochrome P450 Modulation

Herbals alter drug metabolism via CYP450 enzymes, risking toxicity in narrow therapeutic agents (Sparreboom et al., 2004). Cancer patients face heightened interaction risks from 13-63% herbal use. Prediction models lag clinical data.

Regulatory Standardization

Phytotherapeutic agents lack uniform quality control and guidelines (Calixto, 2000). Toxic contaminants further complicate safety (Chan, 2003). Marketing without evidence hinders safe polypharmacy assessment.

Essential Papers

1.

The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety

Martins Ekor · 2014 · Frontiers in Pharmacology · 3.6K citations

The use of herbal medicinal products and supplements has increased tremendously over the past three decades with not less than 80% of people worldwide relying on them for some part of primary healt...

2.

Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents)

João Β. Calixto · 2000 · Brazilian Journal of Medical and Biological Research · 1.3K citations

This review highlights the current advances in knowledge about the safety, efficacy, quality control, marketing and regulatory aspects of botanical medicines. Phytotherapeutic agents are standardiz...

3.

Clinical practice guidelines on the evidence‐based use of integrative therapies during and after breast cancer treatment

Heather Greenlee, Melissa J. DuPont‐Reyes, Lynda G. Balneaves et al. · 2017 · CA A Cancer Journal for Clinicians · 740 citations

Abstract Answer questions and earn CME/CNE Patients with breast cancer commonly use complementary and integrative therapies as supportive care during cancer treatment and to manage treatment‐relate...

4.

Some aspects of toxic contaminants in herbal medicines

Kelvin Chan · 2003 · Chemosphere · 633 citations

5.

A Comprehensive Review of Health Benefits of Qigong and Tai Chi

Roger Jahnke, Linda Larkey, Carol Rogers et al. · 2010 · American Journal of Health Promotion · 564 citations

Research has demonstrated consistent, significant results for a number of health benefits in RCTs, evidencing progress toward recognizing the similarity and equivalence of Qigong and Tai Chi.

6.

Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents

Alex Sparreboom, Michael C. Cox, Milin Acharya et al. · 2004 · Journal of Clinical Oncology · 473 citations

Purpose Interest in the use of herbal products has grown dramatically in the Western world. Recent estimates suggest an overall prevalence for herbal preparation use of 13% to 63% among cancer pati...

7.

Physical exercise intervention in depressive disorders: Meta‐analysis and systematic review

Torbjörn Josefsson, Magnus Lindwall, Trevor Archer · 2013 · Scandinavian Journal of Medicine and Science in Sports · 470 citations

Previous meta‐analyses investigating the effect of exercise on depression have included trials where the control condition has been categorized as placebo despite the fact that this particular plac...

Reading Guide

Foundational Papers

Start with Ekor (2014, 3611 citations) for global usage and safety issues overview; follow Sparreboom et al. (2004, 473 citations) for anticancer interaction mechanisms; Calixto (2000, 1255 citations) for regulatory baselines.

Recent Advances

Greenlee et al. (2017, 740 citations) evidence for integrative cancer therapies; James et al. (2018, 450 citations) on SSA TCAM patterns; Welz et al. (2018, 430 citations) user motivations.

Core Methods

Core techniques: CYP450 inhibition assays (Sparreboom et al., 2004), adverse event pharmacovigilance (Ekor, 2014), quality control standardization (Calixto, 2000), and clinical guideline integration (Greenlee et al., 2017).

How PapersFlow Helps You Research Herbal Drug Interactions

Discover & Search

Research Agent uses searchPapers and citationGraph to map Ekor (2014) centrality in 3611-cited safety monitoring, then exaSearch uncovers polypharmacy risks in cancer contexts, and findSimilarPapers reveals Sparreboom et al. (2004) clusters on anticancer interactions.

Analyze & Verify

Analysis Agent applies readPaperContent to extract CYP450 mechanisms from Sparreboom et al. (2004), verifies claims via CoVe against Ekor (2014), and runs PythonAnalysis on prevalence data (13-63%) for statistical meta-analysis with GRADE grading of clinical evidence levels.

Synthesize & Write

Synthesis Agent detects gaps in pharmacovigilance post-Ekor (2014), flags contradictions between Calixto (2000) regulations and Chan (2003) contaminants; Writing Agent uses latexEditText, latexSyncCitations for Ekor/Sparreboom, latexCompile reports, and exportMermaid for interaction pathway diagrams.

Use Cases

"Extract prevalence stats from herbal interaction papers and compute meta-analysis confidence intervals."

Research Agent → searchPapers('herbal drug interactions prevalence') → Analysis Agent → readPaperContent(Ekor 2014, Sparreboom 2004) → runPythonAnalysis(pandas meta-analysis on 80% global use, 13-63% cancer stats) → CSV export of CI plots.

"Draft LaTeX review on St. John's Wort-warfarin interactions citing top papers."

Synthesis Agent → gap detection (CYP modulation gaps) → Writing Agent → latexEditText(structured review) → latexSyncCitations(Ekor 2014, Sparreboom 2004) → latexCompile(PDF) → researcher gets formatted manuscript with diagrams.

"Find code for herbal pharmacokinetic simulation models from papers."

Research Agent → searchPapers('herbal CYP450 simulation') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets runnable PK models linked to Sparreboom et al. (2004) data.

Automated Workflows

Deep Research workflow conducts systematic review of 50+ papers on herbal safety (Ekor 2014 core), chaining searchPapers → citationGraph → GRADE reports on interaction risks. DeepScan applies 7-step CoVe analysis to verify Sparreboom et al. (2004) claims against contaminants (Chan 2003). Theorizer generates risk assessment models from Calixto (2000) guidelines and Greenlee et al. (2017) clinical data.

Frequently Asked Questions

What defines Herbal Drug Interactions?

Interactions occur via pharmacokinetic (absorption, metabolism via CYP450) or pharmacodynamic effects between herbals and drugs, risking efficacy loss or toxicity.

What methods assess herbal safety?

Methods include pharmacovigilance monitoring (Ekor, 2014), in vitro CYP450 assays, and clinical outcome tracking in polypharmacy (Sparreboom et al., 2004).

What are key papers on this topic?

Ekor (2014, 3611 citations) covers adverse reactions; Sparreboom et al. (2004, 473 citations) details cancer drug risks; Calixto (2000, 1255 citations) addresses standardization.

What open problems exist?

Challenges include real-time interaction prediction models, global pharmacovigilance standardization, and scaling clinical trials for common herb-drug pairs beyond cancer contexts.

Research Complementary and Alternative Medicine Studies with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Herbal Drug Interactions with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers